One of these strategies is a combined administration of a liposomal nanoformulation of HER2/neu-derived P5 peptide together with PEGylated liposomal Dox (Doxil®) to treat HER2+ tumor-bearing mice, aiming to inhibit the MDSCs via Doxil® and induce a stronger immune response upon the liposomal P5 immunotherapy. This evidence concerns the gene ERBB2 and neoplasm.